Improving the quality of our lives through state-of-the-art R&D capabilities.

Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem's new growth engine in the mid to long term.

We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.

LG Chem has been strengthening competitiveness in the glabal market with its WHO–approved hepatits B and pentavalent combination (5-in-1) and Polio vaccine.

EuvaxB^™ Inj.
Immunization against infection caused by all known subtypes of Hepatitis B virus
0.5 mL (10 μg HBsAg) is administered to neonates, infants, and children aged up to 15 years and 1.0 mL (20 μg HBsAg) is administered to adults aged from 16 years, by intramuscular injection
* Basic immunization schedule: 0-1-6 months
* Alternate immunization schedule: 0-1-2 months

Eupenta^™ Inj.
For active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b disease in infants from 6 weeks of age.
Recommended Dosage: Intramuscular injections of 3 doses (1 dose=0.5 mL) at 6, 10, and 14 weeks of age

Eupolio^™ Inj.
For active primary immunization against poliomyelitis caused by poliovirus in infants from 6 weeks of age.
(One pediatric dose is 0.5mL) The first dose should be given at least at the age of 6 weeks, and two subsequent doses should be given at minimum intervals of 4 weeks.